TKL Research appoints vp of operational excellence

US CRO hires Kevin Vernarec

Kevin Vernarec has been appointed to the newly created position of vice president of operational excellence at US clinical research organisation TKL Research.

Vernarec has previously held a variety of operational roles at multinational CROs covering global project management, clinical operations, proposals, budgeting and costing, CTMS and EDC systems implementation, vendor management, process re-engineering and project planning and tracking.

Headquartered in Rochelle Park, New Jersey, TKL Research provides clinical trial management services for Phase I-IV clinical research studies, including an inpatient Phase I facility and outpatient specialised research clinics.

You may also like

Regulatory

TKL Research agrees to sell clinical trials division

TKL Research, a dermatology specialty clinical research organization (CRO), announced today that it has signed an agreement to sell its Clinical Trials Division (CTD) to QuintilesIMS.
Regulatory

AMR Bio urges US policymakers to make infection prevention a core AMR strategy

Submitted ahead of PACCARB's 27th public meeting, AMR Bio's recommendations call for topical antimicrobials such as MRSA-active XF-73 to receive federal support alongside conventional antibiotic development
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development

Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies

Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NICE approval is not enough: why the UK’s next medicines challenge is operational delivery

A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR
Subscribe now